

43. The protein according to claim 42 wherein said protein has the amino acid sequence set forth in SEQ ID NO:1.

44. An isolated protein having the amino acid sequence set forth in SEQ ID NO:1, or portion of said amino acid sequence set forth in SEQ ID NO:1 of at least 10 consecutive amino acids.

45. The protein according to claim 44 wherein said protein has the amino acid sequence set forth in SEQ ID NO:1, or portion of said amino acid sequence set forth in SEQ ID NO:1 of at least 50 consecutive amino acids.

46. The protein according to claim 44 wherein said protein has the amino acid sequence set forth in SEQ ID NO:1, or portion of said amino acid sequence set forth in SEQ ID NO:1 of at least 100 consecutive amino acids.

47. The protein according to claim 44 wherein said protein has the amino acid sequence set forth in SEQ ID NO:1, or portion of said amino acid sequence set forth in SEQ ID NO:1 of at least 240 consecutive amino acids.

48. A fusion protein comprising a protein: i) that has the amino acid sequence set forth in SEQ ID NO:1, or ii) that has an amino acid sequence encoded by a nucleic acid sequence that hybridizes to the nucleic acid sequence set forth in SEQ ID NO:2 at 55°C in 3x saline/sodium citrate (SSC) comprising 0.1% sodium dodecylsulfate (SDS) and that remains hybridized when subjected to washing at 55°C with 1x SSC comprising 0.1% SDS.

49. The fusion protein according to claim 48 wherein said protein has the amino acid sequence set forth in SEQ ID NO:1.

50. A composition comprising a protein: i) that has the amino acid sequence set forth in SEQ ID NO:1, or ii) that has an amino acid sequence encoded by a nucleic acid sequence that hybridizes to the nucleic acid sequence set forth in SEQ ID NO:2 at 55°C in 3x saline/sodium citrate (SSC) comprising 0.1% sodium dodecylsulfate (SDS) and that remains hybridized when subjected to washing at 55°C with 1x SSC comprising 0.1% SDS, and a pharmaceutically acceptable carrier.

51. The composition according to claim 50 wherein said protein has the amino acid sequence set forth in SEQ ID NO:1.

52. The composition according to claim 50 wherein said composition is a pharmaceutical composition and said carrier is a pharmaceutically acceptable carrier.

53. The composition according to claim 51 wherein said composition is a pharmaceutical composition and said carrier is a pharmaceutically acceptable carrier.

54. A fusion protein comprising a protein having the amino acid sequence set forth in SEQ ID NO:1, or portion of said amino acid sequence set forth in SEQ ID NO:1 of at least 10 consecutive amino acids.

55. The fusion protein according to claim 54 wherein said protein has the amino acid sequence set forth in SEQ ID NO:1, or portion of said amino acid sequence set forth in SEQ ID NO:1 of at least 50 consecutive amino acids.

56. The fusion protein according to claim 54 wherein said protein has the amino acid sequence set forth in SEQ ID NO:1, or portion of said amino acid sequence set forth in SEQ ID NO:1 of at least 100 consecutive amino acids.